The return of thalidomide
The 'most reviled drug of the 20th century' is making a comeback, says Amanda Schaffer in Slate. And it might just help you live longer
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
You are now subscribed
Your newsletter sign-up was successful
Thalidomide, the notorious sedative that caused a wave of birth defects in the 1950s and 1960s, is "on its way to a second act," says Amanda Schaffer in Slate. The drug caused a scandal after women who had taken it as a cure for morning sickness gave birth to phocomelic children — with undeveloped or missing limbs and features. But 50 years later, the drug is steadily gaining respectability after being approved by the FDA for the treatment of leprosy and bone marrow cancer, and, astonishingly, showing promise as an "immune booster for the elderly." If this keeps up, the "most reviled drug of the 20th century" might end up being a significant lifesaver in the 21st, writes Schaffer. Here's an excerpt:
Today, scientists are investigating [thalidomide] and a close chemical cousin, to treat conditions from lupus to psoriasis and even as an immune booster for the elderly. This possibility is especially stunning because it means contemplating widespread usage of this class of drugs in basically healthy people and in a group old enough to recall the thalidomide tragedy firsthand...
For scientists to think of these compounds for broad usage, especially in people who aren't very sick, represents a profound comeback ... Considering how tough it is to get new drugs approved, though, the lesson of thalidomide is that it makes sense to look back at old ones and their chemical relatives. Even a former villain, put to a new task, can have a second life.
Article continues belowThe Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Read the entire article in Slate.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com